Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,236 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: steroids Clear all
Completed Phase 4 Interventional

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

NCT00650468
View directory record Official record
Conditions
Renal Transplantation
Interventions
tacrolimus, CellCept, steroids (methylprednisone or prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
29
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Sep 2, 2026, 5:19 AM EDT
Recruiting Phase 1 Interventional

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

NCT06918990
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Carfilzomib, Belatacept
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 5:19 AM EDT
Recruiting Phase 4 Interventional

Subjective Intraoperative Use of Epidural Steroid Administration Following Discectomy

NCT04182997
View directory record Official record
Conditions
Lumbar Disc Herniation
Interventions
Dexamethasone, saline 0.9%
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 5:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ABBV-453, Daratumumab, Dexamethasone, Pomalidomide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT04996160
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Palbociclib, Dexamethasone, Bortezomib, Doxorubicin
Drug
Lead sponsor
Tanja Andrea Gruber
Other
Eligibility
Up to 25 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

NCT03418324
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRC105, Abiraterone, Enzalutamide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 2, 2026, 5:19 AM EDT
Not listed Not applicable Interventional

Korean Medicine for Symptomatic Lumbar Spinal Spondylolisthesis

NCT03107468
View directory record Official record
Conditions
Spondylolisthesis, Lumbosacral Region
Interventions
Mokhuri intensive treatment, Non-surgical conventional standard treatment
Other
Lead sponsor
Kim Ki Ok
Other
Eligibility
19 Years to 78 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Phase 4 Interventional

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

NCT00073710
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 1, 2006 · Synced Sep 2, 2026, 5:19 AM EDT
Terminated Not applicable Interventional

Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease

NCT00152620
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Dexamethasone, Methylprednisolone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 2, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

NCT00365274
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 2, 2026, 5:19 AM EDT
Terminated Not applicable Interventional Results available

Vitamin D Deficiency and Atopic Dermatitis

NCT01337635
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency
Interventions
Vitamin D
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

NCT01234025
View directory record Official record
Conditions
Castrate-Resistant Prostate Cancer
Interventions
ISIS EIF4E Rx, Prednisone, Docetaxel
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 2, 2026, 5:19 AM EDT
Withdrawn Phase 4 Interventional

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376
View directory record Official record
Conditions
Herpes Simplex Virus Keratitis
Interventions
oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Results available

Cryotherapy in Treating Patients With Primary Stage I Non-Small Cell Lung Cancer or Lung Metastasis

NCT00890617
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
Cryotherapy (PTC), Prednisone
Procedure · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Phase 1 Interventional

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

NCT03283917
View directory record Official record
Conditions
Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions
Daratumumab, Dexamethasone, Ixazomib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

NCT01994590
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dovitinib, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 2, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

NCT04400890
View directory record Official record
Conditions
COVID-19
Interventions
Resveratrol, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Marvin McCreary, MD
Other
Eligibility
45 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 2, 2026, 5:19 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

NCT02339740
View directory record Official record
Conditions
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Interventions
Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 2, 2026, 5:19 AM EDT
Recruiting Early Phase 1 Interventional

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

NCT06137040
View directory record Official record
Conditions
Asthma in Children, Asthma Attack
Interventions
Magnesium Sulfate within the first hour, No Magnesium sulfate within the first hour
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 2, 2026, 5:19 AM EDT
Enrolling by invitation Phase 2 Interventional

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 2, 2026, 5:19 AM EDT
Not listed Early Phase 1 Interventional

To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

NCT03975374
View directory record Official record
Conditions
Blepharo Conjunctivitis
Interventions
Tobramycin/dexamethasone opthalmic solution, Tobradex Opthalmic Solution
Drug
Lead sponsor
Sutphin Drugs
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

NCT00934843
View directory record Official record
Conditions
Congenital Heart Disease, Disorder of Fetus or Newborn
Interventions
methylprednisolone (IVMP), methylprednisolone (two doses IVMP)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Up to 30 Days
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2011 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 2, 2026, 5:19 AM EDT
Completed Not applicable Interventional Results available

Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications

NCT01406015
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 2, 2026, 5:19 AM EDT